Figure 1:
MRI scan (FLAIR Sequence) at the time of diagnosis (A); at the time of progression, before starting TPCV (B); 6 months after initiation of TPCV (C); 18 months after completion of TPCV (D)
References
1. Reddy AT, Packer RJ. Chemotherapy for low-grade gliomas. Child’s nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 1999;15 (10): 506-13.
2. Packer RJ, Pfister S, Bouffet E, et al. Pediatric low-grade gliomas: implications of the biologic era.Neuro-oncology 2016.
3. Hargrave DR, Bouffet E, Tabori U, et al. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clinical cancer research : an official journal of the American Association for Cancer Research 2019;25 (24): 7303-11.
4. Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. The Lancet Oncology 2019; 20 (7): 1011-22.
5. Nobre L, Zapotocy M, Ramaswamy V, et al. Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology 2020; 4 : 561-71.
6. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nature genetics 2013; 45 (6): 602-12.
7. Ryall S, Zapotocky M, Fukuoka K, et al. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell 2020; 37 (4): 569-83 e5.
8. Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017;35 (25): 2934-41.
9. Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology : official journal of the European Society for Medical Oncology 2017; 28 (7): 1631-9.
10. Mulcahy Levy JM, Zahedi S, Griesinger AM, et al. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. eLife 2017;6 .
11. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012; 30 (21): 2641-7.